Cardax, Inc. Stock Price - CDXI

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cardax, Inc. (QB) CDXI OTC BB Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.0475 0.00 0.00 0.00 0.0475 19:00:00
Bid Price Ask Price Spread Spread % News
0.035 0.055 0.02 36.36% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Cardax, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 6.50M 136.79M $ -4.26M - - 55.87M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cardax, Inc. News

Loading Messages....

Latest CDXI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CDXI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.050.0550.045050.048070823,942-0.0025-5.0%
1 Month0.060.060.04010.049994717,019-0.0125-20.83%
3 Months0.100.250.0320.068223945,187-0.0525-52.5%
6 Months0.130.250.0320.077235741,970-0.0825-63.46%
1 Year0.190.250.0320.105969637,447-0.1425-75.0%
3 Years0.100.590.0320.199804549,019-0.0525-52.5%
5 Years0.300.950.030.181394144,688-0.2525-84.17%

Cardax, Inc. Description

Cardax is a biopharmaceutical company engaged in the development and commercialization of dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. Cardax's product platform consists of a commercially available dietary supplement, ZanthoSyn, and pharmaceutical candidates, CDX-101 and CDX-301, which are in pre-clinical development for cardiovascular and macular disorders. The safety and efficacy of the Company's products have not been directly evaluated in clinical trials or confirmed by the FDA.

Your Recent History
Cardax, In..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.